Harman Law LLC

Tylenol Recalls and Liver Failure

Harman Law LLC Media — Tue, 21 May 2013 10:08:13 +0000

The popular over the counter painkiller Tylenol® has been the subject of recalls due to quality and manufacturing problems. Since 2009, McNeil Consumer Products/Janssen (subsidiaries of Johnson & Johnson) has recalled different formulations of Tylenol® worldwide for a variety of problems that could affect patient health including in some cases liver failure. Elevated levels of acetaminophen above the dosage listed on labeling have been documented in some of the formulations, increasing the risks.

Consumers are advised to discontinue use of Tylenol if there is an unusual odor or if the lot number is included on this list of Johnson & Johnson recalled products. Although the recalled products have been removed from stores, consumers may still have previously purchased Tylenol.

If you have taken one of the products from the recalled lots, keep the intact product bottle, box, or blister pack with the lot, expiration date and any remaining product.

If you have experienced side effects including liver failure or abnormal liver enzymes during or after taking Tylenol®, contact our office immediately at 888-55-HARMAN to learn more about your legal rights and potential compensation for injury. You may also fill out the inquiry form here.

Harman Law Firm offers no cost, no obligation consultations to consumers who believe they may have been harmed by defective drugs, devices, and consumer products.

Related information

“Janssen’s manufacturing problems may lead to criminal charges in Korea” by Dan Stanton, in-pharmatechnologist.com, May 20, 2013

“J&J dealing with OTC manufacturing issues on 3 continents” by Eric Palmer, Fierce Pharma Manufacturing, May 6, 2013

Toxic Benzene Ground and Water Exposure: Lawsuit Filed on Behalf of Child with Leukemia

Harman Law LLC Media — Tue, 21 May 2013 08:41:26 +0000

Harman Law filed a complaint and is continuing to pursue defendants on behalf of a child who developed leukemia specific to benzene exposure while living near a petroleum transport station. For years, the station used by BP, Chevron, Gulf and other oil companies illegally disposed of toxic material including benzene resulting in documented contamination of the ground near the family’s home and in their drinking water supply.

The complaint is filed in the Superior Court of Athens-Clarke County, Georgia by Harman Law LLC and Nidel Law PLLC of Washington, D.C.

Related information

J.M. as Parent and next friend of minor son J.M.M. v. BP Products North America Inc.; Chevron U.S. A. Inc.,; Gulf Oil Corporation; Union Oil Company of California; Transmontaigne Product Services, Inc.: Transmontaigne Product Services Inc. East; Louis Dreyfus Highbridge Energy LLC; Colonial Pipeline Company; and Plantation Pipe Line Company

“Lawsuit claims petroleum leaks caused child’s leukemia” by Lee Shearer, Athens Banner-Herald/Online Athens, December 29, 2011

“Lawsuit filed against EPA for Pollution Reporting Failures at Refineries and Chemical Plants” by Environmental Protection Website, May 2, 1013

COMPLAINT FILED Nov 15 2011_JMM for minor son JMM v BP Chevron Gulf Union Transmontaigne Colonial Dreyfus Plantation

Harman Appearing on The American Law Journal from CNN Atlanta

Harman Law LLC Media — Wed, 01 May 2013 20:03:24 +0000

From the CNN Atlanta studios, Attorney Matthew Harman will appear on the legal television program The American Law Journal discussing the U.S. Food and Drug Administration.

The program will air on the Philadelphia CNN-News affiliate WFMZ June, 2013 and online at www.YouTube.com/LawJournalTV.

Medtronic Drug Infusion Pump Failures and Recall

mharman — Tue, 30 Apr 2013 23:17:38 +0000

UPDATE: The Harman Law Firm has filed a lawsuit on behalf of a young woman who died while using a Medtronic Insulin pump. For more information, see link below.

The FDA has notified healthcare professionals that Medtronic Drug Infusion Pumps could fail if they are used with drugs not approved for the devices. The consequences could be severe adverse health events including death.

When medications used in the pump are not approved for the device, the motor may stall intermittently or fail permanently, ceasing the infusion of drugs as prescribed. Patients may not be aware the pump has failed until they experience a potentially serious medical issue.

The Medtronic recalled implantable drug infusion pump models are:

SynchroMed II
SynchroMed EL

The FDA says this Class 1 recall is the most serious type of recall and involve situations in which there is a reasonable probability that use of these products will cause serious adverse health consequences or death.

Our firm is investigating cases nationwide where these pumps may be responsible for injury or death.

If you or someone you know has one of these pumps and experienced a failure or other problem, contact our office immediately by filling out the brief questionnaire or call 888-554-2762 for a free consultation and evaluation of your situation. You may be eligible for compensation.

As with any medical issue, if you currently experiencing side effects consult your healthcare professional immediately.

Links

Harman Law Firm Files Lawsuit for Woman Injured by Medtronic Mini-Med Infusion Pump

“Medtronic Recalls Drug Pumps After Infusion Failures“, Bloomberg News, Dec. 21, 2012

“Medtronic Drug Infusion Pumps: Recall – Intermittent or Permanent Pump Motor Stall“, U.S. Food and Drug Administration, December 21, 2012

Update on Granuflo and NaturaLyte Dialysis Treatment: Risk of Death, Heart Attack

mharman — Mon, 15 Apr 2013 09:33:37 +0000

The FDA issued a Class 1 recall for dialysis treatment concentrates Granuflo and NaturaLyte after 941 patients in 2010 suffered heart attacks while being treated with the substances. Fresenius Medical Care North America is being investigated for failing to warn the over 130,000 dialysis patients they treat each year of the risks.

If you or someone you know has experienced side effects as a result of dialysis treatments at Fresenius or other dialysis centers, regardless if you know if the treatment included Granuflo or NaturaLyte, contact our office immediately at 888-554-2762 or write us using this contact form.

You may have limited time to file a claim. Harman Law Firm offers no cost, no obligation consultations to patients who believe they may have been affected by defective, dangerous drugs and medical devices.

Related information

“Dialysis Company’s Failure to Warn of Product Risk Draws Inquiry” by Andrew Pollack, The New York Times, June 14, 2012

“FDA Class 1 Recall: Fresenius Medical Care North America, Naturalyte and Granuflo Acid Concentrate” March 29, 2012

Parents of Premature Babies in Oxygen Research Study Not Warned of Risks

mharman — Sun, 14 Apr 2013 20:46:15 +0000

Parents of premature babies in a four-year study of oxygen level treatment were not sufficiently warned of the potential dangers of the experiments. The families of over one thousand babies could have been at risk of blindness, brain damage or death as a consequence of their participation in the research.

The U.S. Department of Health and Human Services criticized lead researchers at the nearly two dozen participating medical schools for inadequate informed consent. Emory University Medical School in Atlanta participated in the study.

The attorneys at Harman Law Firm are investigating any harm to babies that may have occurred during their involvement in the research. If you or a family you know has an infant who was in the study at Emory or any research center who experienced a health problem contact our firm immediately to learn your options and protect the child’s health in the future. Fill out our contact form, email info@harmanlaw.com, or call toll-free 888-554-2762.
Links

“Parents Not Warned of Risk in Premature Infants Study,” The Boston Globe, April 11, 2013

“Feds Say Study of Babies at UM, Elsewhere Should Have Disclosed Risks,” The Miami Herald, April 10, 2013

“Study of Babies Did Not Disclose Risks, U.S. Finds,” The New York Times, April 10, 2013

VIDEO: “Inadequate Consent in Premie Study,” Democrat and Chronicle/Gannett News, April 11, 2013

Auto Accidents

mharman — Sun, 14 Apr 2013 10:34:13 +0000

How do you or your loved ones know who to call when you’ve been injured in an auto accident? Do you call an attorney or law firm you saw advertised? Ask friends for referral? Call the local bar association?

At Harman Law, we know people who are injured must often make a quick decision on what attorney to consult for representation of their best interests. Insurance companies may pressure you to accept a settlement before you even know the full extent of your injuries or begin to think about calling a lawyer. These settlements may not take into account the severity of injuries over the long term, your medical expenses and physical therapy, and other needs beyond the time you’re offered the settlement.

One call to 888-55-HARMAN brings peace of mind through an initial no cost, no obligation review of your situation. You pay nothing unless we win your case.

The attorneys at the Harman Law Firm are compassionate defenders of ordinary people injured in extraordinary circumstances. Join forces with a law firm that doesn’t push to settle just to be done with the case without considering the long term effects of the accident. Victims of accidents need an attorney who is assertive (and aggressive if needed) to represent them.

Write us on this inquiry form or call 888-55-HARMAN before discussing the accident with anyone other than the police or medical professionals.

Related information

“How to choose personal injury lawyers” DMV.org

Medtronic MiniMed Paradigm Insulin Pump: Lawsuit Filed

mharman — Fri, 12 Apr 2013 13:01:51 +0000

The Harman Law Firm has filed a complaint against the manufacturer of the Medtronic MiniMed Paradigm MMT 722 Insulin Pump following the death of a young woman who was using the device.

The MiniMed Insulin Pump is designed to deliver insulin continuously into the body, making multiple injections per day unnecessary. The young college student with the MiniMed pump died from “diabetic ketoacidosis,” a condition that results from uncontrolled blood sugar that can quickly lead to heart failure, kidney failure, coma or death.

The complaint alleges that the MiniMed pump was defective and malfunctioned and that the manufacturer tested the pump following the woman’s death and concluded that the pump was in fact defective with a “faulty microchip” and “broken solder on joint on the interface board.” The manufacturer’s testing also concluded that the pump was “unable to prime,” meaning it could not eliminate air in the system so that it could pump the correct amount of pure insulin.”

Attorney Matthew Harman and the firm’s associates are continuing to investigate injuries that may be a result of using any of Medtronic drug pump model, including the recalled SynchroMed II and SynchroMed EL in addition to the MiniMed Paradigm insulin pump. For more information, see this page on the recall of Medtronic drug pumps.

If you or someone you know has experienced harm from a Medtronic drug or insulin pump, contact us for a free, no obligation consultation to learn your rights. You may be entitled to compensation, though there may be a time limit to file a claim.

If you are currently experiencing any health-related issues, consult your medical professional immediately.

Pradaxa and Xarelto Blood Thinners: Risk of Death, Serious Bleeding, Stroke or Heart Attack

mharman — Thu, 04 Apr 2013 08:43:37 +0000

Patients taking the blood thinner and anti-blood clot drugs Pradaxa® and Xarelto® may be at risk, particularly patients with impaired kidney function.

If someone you know has died or has experienced sudden, serious bleeding, heart attack, stroke, or other side effect while taking these drugs, contact our office immediately by calling 888-554-2762 or filling out the online contact form here.

Pradaxa® (generic name dabigatran) and Xarelto® (rivaroxavan) are the newest in the category of blood thinning drugs. Previous treatment protocols included warfarin, also known by the brand names Coumadin®, Jantoven® and Marfarin®, developed in the 1950′s and used with little risk since that time.

Pradaxa®, approved by the FDA in 2010, is manufactured by Boehringer and Xarelto® by Johnson & Johnson.

Related information

“Dabigatran and Postmarketing Reports of Bleeding” New England Journal of Medicine, April 4, 2013

“FDA Drug Safety Communication: Update on the risk for serious bleeding events with the anticoagulant Pradaxa (dabigatran)” November 2, 2012

“JAMA says FDA jumped the gun on Gilenya, Pradaxa” by Tracy Staton, Fierce Pharma, September 5, 2012

Dialysis Related Injury and Death

mharman — Thu, 06 Dec 2012 18:23:46 +0000

The use of GranuFlo^® and NaturaLyte^® for dialysis have been linked to serious side effects including heart attack, stroke, and death.

On March 29, 2012, the U.S. Food and Drug Administration issued a recall of GranuFlo^® and NaturaLyte^®, finding that they are associated with low blood pressure, cardiac arrhythmia, heart attack, cardiac arrest and other cardiovascular problems.

The manufacturer of GranuFlo^® and NaturaLyte^®, Fresenius Medical Care, serves a majority of the entire American dialysis market.

If you or a loved one has suffered a cardiac injury within 48 hours of dialysis treatment, you may be entitled to compensation. Contact the experienced attorneys at Harman Law LLC for a free case evaluation.